Beixinke Chemical Achieves 99.89% Purity for Cdc42 Inhibitor ML 141, Enabling More Reproducible Research
Shanghai, China — June 22, 2026 — Beixinke Chemical, a research-driven custom synthesis company, today announced the successful delivery of high-purity ML 141 (CAS 71203-35-5) at multi-kilogram scale, with batch purity reaching 99.89% as verified by orthogonal analytical methods.
A Critical Tool for Cdc42 Research
ML 141 is a selective, reversible inhibitor of Cdc42 GTPase (IC50 ≈ 200 nM), a key regulator of actin cytoskeleton dynamics,
cell polarity, and cell migration. Since its characterization by Surviladze et al. (2010), ML 141 has become one of the most
widely cited chemical probes for dissecting Cdc42-dependent phenotypes — including tumor cell invasion, filopodia
formation, and intracellular trafficking — while showing minimal activity against closely related Rho family GTPases such as
Rac1 and RhoA.
For researchers investigating metastatic mechanisms or validating Cdc42 as a therapeutic target, inhibitor purity is not a
footnote — it is the foundation of interpretable data. Even trace impurities with structural similarity to the target chemotype
can introduce off-target effects, clouding dose-response relationships and undermining experimental reproducibility.
99.89%: Purity That Translates to Data Confidence
Beixinke Chemical's ML 141 consistently surpasses the industry benchmark, with the latest production batch
achieving 99.89% purity as determined by HPLC peak area normalization — a total impurity burden below 0.11%.
This result was cross-validated by LC-MS and ¹H/¹³C NMR, ensuring both chromatographic and spectroscopic integrity.
"When a customer runs a Cdc42 inhibition assay, they should be observing the biology of ML 141 —
not the off-target noise of a synthetic byproduct," said a Beixinke Chemical representative.
"We apply this standard not just to ML 141, but to every inhibitor and chiral building block that leaves our laboratory."
From Milligram Exploration to Kilogram Delivery: One Partner, Full Traceability
This achievement reflects Beixinke Chemical's integrated approach bridging discovery chemistry and process scale-up:
●Process Development: Optimized synthetic route enabling seamless transition from milligram-scale proof-of-concept to kilogram-scale manufacture without purity degradation.
●Analytical Rigor: A three-method panel — HPLC (purity), LC-MS (identity + impurity profiling), and NMR (structural confirmation) — applied to every batch.
●Batch-to-Batch Consistency: Tight process controls and standardized purification protocols ensure reproducible purity across multiple production lots, backed by comprehensive Certificates of Analysis.
Operating over 1,000 m² of fully equipped laboratories, the company supports custom synthesis workflows from exploratory synthesis to full process scale-up, with demonstrated capability in heterocyclic pharmaceutical intermediates, chiral building blocks, and inhibitor-type small molecules.
Trusted by Global Research Institutious
Beixinke Chemical's high-purity ML 141 has already been supplied to research groups at a prominent international biomedical research institute and a biopharmaceutical company, supporting Cdc42-focused projects at various stages from target validation to preclinical profiling. The company welcomes additional inquiries from academic and industry teams seeking reliable, high-purity chemical probes and intermediates.
Availability and Further Information
High-purity ML 141 (CAS 71203-35-5) is available now. Researchers and procurement professionals are invited to request:
●Certificates of Analysis (CoA) with HPLC, LC-MS, and NMR data
●Sample quantities for evaluation
●Custom synthesis quotations for analogs and derivatives
Contact:
https://www.beixinkechem.com